Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $345.4 million.

  • Madrigal Pharmaceuticals' Accumulated Expenses rose 16364.43% to $345.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.4 million, marking a year-over-year increase of 16364.43%. This contributed to the annual value of $124.7 million for FY2024, which is 3858.08% up from last year.
  • As of Q3 2025, Madrigal Pharmaceuticals' Accumulated Expenses stood at $345.4 million, which was up 16364.43% from $157.5 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Accumulated Expenses' 5-year high stood at $345.4 million during Q3 2025, with a 5-year trough of $44.1 million in Q1 2021.
  • For the 5-year period, Madrigal Pharmaceuticals' Accumulated Expenses averaged around $102.1 million, with its median value being $85.6 million (2023).
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Accumulated Expenses crashed by 161.93% in 2023, and later skyrocketed by 16364.43% in 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Accumulated Expenses (Quarter) stood at $55.0 million in 2021, then skyrocketed by 66.15% to $91.5 million in 2022, then decreased by 1.62% to $90.0 million in 2023, then skyrocketed by 38.58% to $124.7 million in 2024, then surged by 176.98% to $345.4 million in 2025.
  • Its Accumulated Expenses was $345.4 million in Q3 2025, compared to $157.5 million in Q2 2025 and $124.2 million in Q1 2025.